Does anyone could guess which `biotech/medical stock Jeff Brown is promoting in the ”Penny IPO`s” pitch? All of them have potential for at least 10x growth. Here is the link to the pitch https://secure.bonnerandpartners.com/?cid=MKT459805&eid=MKT463356&step=start&plcid=PLC069177&SNAID=SAC0010464081&email=jozef.szlufcik@gmail.com&encryptedSnaid=mtFugfkIjQZwvQduYvOPoJkMUqW8Rkx1t2V4kZtac6o%3D&emailjobid=4646829&emailname=20200520-TBE-F&assetId=AST136084&page=2
Grtx,
Zeflik
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Two stocks, from previously decoded by Gumshoe community pitching of Jeff Brown, brought me quite good profit. By this I consider him a good analyst worth listening.
WHAT ARE THEY?
ANY IDEAS HERE
I have not subscribed to the ipo service but have seen the presentation. I’m also in healthcare and familiar with the fda process. I believe IPO 3 is Editas for a few reasons.
In this presentation, and a few others he’s done for other services, there are slides that appear showing FDA trial data. Trial number can be seen, and in a different video for another service, the actual company was shown. Im sure that was a mistake. But the trial numbers were the same across both.
Crisper (gene editing) is patented and only used by a handful of companies. In this presentation, in the background, one can see LCA-10 in a slide that is a bit blurry. This is Leber Congenital Amarousis (congenital blindness). By searching publicly-available trial data, the only company that comes up as having a phase 1/2, in vivo, ongoing trial for autosomal dominant LCA is Editas.
This is it: https://clinicaltrials.gov/ct2/show/NCT03872479
In other slides, current share price is shown and also fits at 20-30, currently around $27 I believe, as does it’s current market cap.
In-vivo gene editing, if successful, would be a first-in-class therapy. Editas also has a few other potential gene targets for other conditions.
I haven’t researched ipo 1 or 2 yet. Interested to hear others’ thoughts.
Yes I can confirm from my side that Editas is one from the companies according to the description. Only doubt I have is if it can be considered as a penny stock?
Agree. Early stage for sure but a penny stock it is not. But if their phase II comes through, and they are the first to cure a major genetic condition with gene editing, the sky’s the limit.
I looked into IPO #1 and think it’s kaleido (kldo). Jeff Gordon is collaborating, they have a focus on using the microbiome to treat hepatic encephalopathy (sequela of cirrhosis), partnership with Janesson, a division of J&J tasked with treating pediatric atopic (allergic) conditions, and they are a microcap in target price range with a planned phase II trial this summer.
This is my opinion only, based on the (misleadingly annotated) charts in Jeff’s presentation and cross-referencing some of the info he shares with Crunchbase: 1 – KLDO, 2 – DTIL, 3 – EDIT.
absolutely right – nailed it on all 3.
stock no 2 confirmation below.
https://www.wraltechwire.com/2020/01/15/precision-biosciences-hits-two-key-fda-milestones-in-advancing-gene-therapy-for-cancer/
i am considering subscribing, are you and actual subscriber and are you please with the service?
I am a paying irregular for several years, so yes, I am happy with it
THANKS! i have dug a little more and i am ready to take the plunge… happy trading!
How do I but stock? Where in north California do I but it. How do i buy it on the Internet?
Got Mr Browns five g play from Travis J and it is up nicely .(akts)